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In our aim to eliminate malaria, more sensitive tools to detect residual transmission
are quickly becoming essential. Antimalarial antibody responses persist in the blood
after a malaria infection and provide a wider window to detect exposure to infection
compared to parasite detection metrics. Here, we aimed to select antibody responses
associated with recent and cumulative exposure to malaria using cross-sectional survey
data from Haiti, an elimination setting. Using a multiplex bead assay, we generated
data for antibody responses (immunoglobulin G) to 23 Plasmodium falciparum targets in
29,481 participants across three surveys. This included one community-based survey
in which participants were enrolled during household visits and two sentinel group
surveys in which participants were enrolled at schools and health facilities. First, we
correlated continuous antibody responses with age (Spearman) to determine which
showed strong age-related associations indicating accumulation over time with limited
loss. AMA-1 and MSP-119 antibody levels showed the strongest correlation with
age (0.47 and 0.43, p < 0.001) in the community-based survey, which was most
representative of the underlying age structure of the population, thus seropositivity to
either of these antibodies was considered representative of cumulative exposure to
malaria. Next, in the absence of a gold standard for recent exposure, we included
antibody responses to the remaining targets to predict highly sensitive rapid diagnostic
test (hsRDT) status using receiver operating characteristic curves. For this, only data
from the survey with the highest hsRDT prevalence was used (7.2%; 348/4,849). The
performance of the top two antigens in the training dataset (two-thirds of the dataset;
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n = 3,204)—Etramp 5 ag 1 and GLURP-R0 (area-under-the-curve, AUC, 0.892 and
0.825, respectively)—was confirmed in the test dataset (remaining one-third of the
dataset; n = 1,652, AUC 0.903 and 0.848, respectively). As no further improvement
was seen by combining seropositivity to GLURP-R0 and Etramp 5 ag 1 (p = 0.266),
seropositivity to Etramp 5 ag 1 alone was selected as representative of current or
recent exposure to malaria. The validation of antibody responses associated with these
exposure histories simplifies analyses and interpretation of antibody data and facilitates
the application of results to evaluate programs.
Keywords: malaria, immunoglobulin G (IgG), multiplex bead assay, sero-surveillance, elimination, ETRAMP
INTRODUCTION
Globally, the number of countries in malaria pre-elimination
and elimination phases is increasing (1). For malaria control
GRAPHICAL ABSTRACT | Flowchart of the selection process for immunoglobulin G (IgG) responses to Plasmodium falciparum antigens representative of cumulative
and current or recent exposure. QC: quality control, hsRDT: highly sensitive rapid diagnostic test, AUC: area under the curve, ROC: receiver operating characteristic,
AMA-1: apical membrane antigen 1, MSP-119: 19 kilodalton fragment of merozoite surface protein 1, GLURP-R2: glutamate rich protein R2, Etramp 5 ag 1: early
transcribed membrane protein 5.
and elimination purposes, the allocation of national resources
is commonly guided by regional case counts. However, trends
in passively detected cases are dependent on health system
coverage and treatment-seeking behavior, and thus may not
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represent the true malaria burden in all settings. Serological
endpoints, typically the presence of antibody responses in
resident populations, represent a population’s exposure history
and can identify areas with residual malaria transmission
more accurately than the prevalence of infection at low
transmission (2).
Until recently, sero-surveillance has primarily focused
on antibodies representing cumulative exposure, such as
Plasmodium falciparum apical membrane antigen 1 (AMA-
1) and the 19 kDa fragment of merozoite surface protein 1
(MSP-119) (2). Age-specific increases in seroprevalence to these
antigens, estimated as seroconversion rates (SCR), have been
shown to be strongly correlated with entomological inoculation
rates (EIR), the gold standard metric for transmission intensity,
and with parasite prevalence (2). Antibodies to these antigens
persist in the blood with repeated exposure. For MSP-119, model
estimates suggested the time to sero-reversion is 23 (3) to 50
years or more (4), while limited data from observational studies
suggest half-lives of long-lived antibody secreting cells to be 2
(5) to 16 (6) years. Although MSP-119 and AMA-1 antibody
half-lives might be faster in children (7, 8), this may be due to
insufficient repeated exposure in children at low transmission.
Antibodies with shorter half-lives [i.e., those indicating incidence
in the past year (9)] may be able to detect if and where changes
in malaria transmission intensity take place more rapidly and
accurately as compared to antibodies with long half-lives. Several
potential candidates have recently been optimized for use in
multiplex bead assays (MBA) (10).
As part of Haiti’s aim to eliminate malaria (11), large-
scale cross-sectional surveys were performed to assess if and
where residual transmission, potentially undetected via routine
surveillance, is occurring. Here, we assessed antibody responses
to 23 P. falciparum recombinant proteins and peptides in
29,481 participants residing in two areas with different levels
of transmission intensity. Our aim was to select antibodies
associated with cumulative and current or recent exposure to
malaria for the Haitian context in order to simplify analyses and
interpretation of collected survey data that can be used to inform
program decisions.
METHODS
Study Population
The island of Hispaniola, consisting of Haiti and the Dominican
Republic, is the last remaining region in the Caribbean with
malaria transmission. In 2016, 97% of the reported malaria cases
on the island occurred in Haiti (12). In Haiti, transmission is
highly focal as the Grand’Anse department, in the southwestern
part of the country, accounted for 47% of the national malaria
cases reported in 2017 (13). Three large-scale cross-sectional
surveys were conducted in Haiti in 2017 (14): (1) in Artibonite,
central Haiti, a community-based household survey (HH-
Artibonite) with 21,891 participants; (2) an easy-access-group
(EAG) survey in the same area (EAG-Artibonite) including
6,006 participants; and (3) an EAG survey was performed
with the same protocol in Grand’Anse, southwestern Haiti,
(EAG-Grand’Anse) with 5,034 participants (Table 1). For the
EAG surveys, participants were enrolled at schools and health
facilities. Although in EAG-Artibonite participants were also
sampled at church venues, these were excluded from further
analyses due to practical and logistical restraints of this sentinel
group (16). At health facilities, participants were enrolled
irrespective of the reason for their visit, and both treatment-
seeking patients as well as accompanying people were asked
to participate. In the HH-Artibonite survey, households were
randomly selected in a defined geographic area and all household
members were asked to participate; participants were tested
at their homes (Hamre et al., in preparation). In both survey
types, people were asked to participate irrespective of the
presence of fever or symptoms of malaria. Participants from
all three cross-sectional surveys provided finger-prick blood
for malaria diagnosis by a conventional rapid diagnostic test
(cRDT; SD Bioline Malaria Antigen P.f., 05FK50, Standard
Diagnostics) and a highly-sensitive RDT (hsRDT; also known
as ultrasensitive RDT, Alere Malaria Ag P.f., 05FK141, Standard
Diagnostics). In addition, finger-prick blood was spotted on
Whatman 903 cards (GE Healthcare), dried overnight at ambient
temperature and packed the next day with silica gel. Dried
blood spots (DBS) were stored at +4◦C and transported
to the national laboratory (Laboratoire National de Santé
Publique; LNSP) in Port-au-Prince weekly. Demographic and
household characteristics were collected through a tablet-based
questionnaire. Participants testing positive by cRDT were treated
according to national guidelines.
Antigen Panel and Covalent Coupling of
Antigens to Beads
Twenty-three P. falciparum antigens and peptides from asexual
life-cycle stages were included in the panel (Table 2). Antigens
were covalently coupled to unique bead regions as described by
Rogier et al. (34). Details on antigen to bead coupling conditions
are described elsewhere for most of the antigens in the panel
(15), while for the remaining six antigens these are provided in
Supplementary Table 1.
Antimalarial Antibody Detection
Immunoglobulin G (IgG) data were collected for all
participants as previously described (34). Antibody levels
were measured using a MBA with a OneStep protocol
enabling a rapid turnaround by incubating sample
and secondary antibody simultaneously overnight (34).
Median fluorescence intensity (MFI) was recorded using
the MAGPIX with Bio-Plex ManagerTM MP software
(BioRad) and corrected for background reactivity to give
a final value of MFI minus background (hereafter: MFI).
Alongside participant samples, a 6-point serial dilution of
a hyperimmune positive control pool (i.e., standard curve)
was added to each plate to assess plate-to-plate variation in
data collection.
Quality Control of Antimalarial Antibody
Data Collection
Plates with results that fell outside of the mean +/- 2 standard
deviations (SD) of the third point of the serial dilution for two out
Frontiers in Immunology | www.frontiersin.org 3 May 2020 | Volume 11 | Article 928
van den Hoogen et al. Plasmodium falciparum Antibodies in Elimination
TABLE 1 | General characteristics of the study population for three malaria cross-sectional surveys performed in Haiti.
Characteristic HH-Artibonite EAG-Artibonite EAG-Grand’Anse
Department Artibonite, central Haiti Artibonite, central Haiti Grand’Anse, southwestern Haiti
Communes Verrettes & La Chappelle Verrettes & La Chappelle Anse-d’Hainault, Chambellan, Dame-Marie,
Les Irois & Moron
Timing Jul-Oct 2017* May-Jun 2017 Nov-Dec 2017
Survey type Community-based
household survey
Easy-access-group survey: participants
recruited in churches, schools & health facilities
Easy-access-group survey: participants
recruited in schools & health facilities
N
- Available IgG data** 21,235 5,898 4,967
- Merged to field data 21,214 4,154*** 4,959
- Aged ≥1 year 20,609 4,019 4,856
Median age,
interquartile range
20, 8–41 12, 8–24 13, 8–22
Highly sensitive RDT
prevalence, n/N
0.76%, 157/20,556 0.77%, 31/4,019 7.18%, 348/4,849
RDT: rapid diagnostic test. IgG: immunoglobulin G.
*Two-week pause due to hurricanes.
**For more information on the number samples for which IgG data was successfully collected see van den Hoogen et al. (15).
***The large decrease in samples is due to the exclusion of participants recruited at church venues from further analyses due to practical and logistical restraints of this sentinel group
(16).
of three highly immunogenic antigens (GLURP-R2, AMA-1 and
MSP-119) were repeated (15). Of the twenty-three P. falciparum
antigens and peptides included in the panel, six had to be
excluded as they showed loss in reactivity over time (previously
described in van den Hoogen et al. (15) and for the remaining
six antigenic targets shown in Supplementary Figure 1):
MSP2_Dd2, MSP2_CH150/9, GEXP18, EBA-140 RIII-V,
Rh2_2030, and Rh4.2. The remaining seventeen antigenic targets
were analyzed for their association with cumulative and current
or recent exposure to falciparummalaria.
Statistical Analyses
Data Standardization
All statistical analyses were performed in R version 3.4.1
(35). After correction for background reactivity, the lowest
MFI value recorded was−61, thus 65 was added to all values
(i.e., for all antigens across all participants) and resulting
MFI values were log10-transformed. Participants with high IgG
responses to glutathione S-transferase (GST) were removed
from further analyses (MFI>1,000) (15). In addition, results
from participants below the age of 1 were excluded from the
dataset to remove any influence of maternally derived antibodies.
Finite mixture models were used to identify two components
in the log10(MFI) participant data and the lower distribution
was assumed to consist of seronegative individuals. Thresholds
for seropositivity were defined as the mean of the lower
distribution plus 5 SD (for details see Supplementary Methods
in Supplementary Data Sheet 2).
Antibody Responses Associated With Cumulative
Exposure
Antibody responses (log10MFIs) from participants were
correlated with age; those that were most strongly correlated
with age were considered to represent cumulative exposure.
Analysis was conducted using the continuous antibody data
instead of seropositivity to maximize the strength of any
correlation. The HH-Artibonite survey was considered most
informative in assessing correlations between antibodies and age,
as it represents the full age-structure of the population sampled
due to its community-based sampling strategy compared to
sentinel group sampling in the EAG-surveys (children attending
school and healthcare-seeking populations sampled at local
facilities). Participants who were hsRDT positive were excluded
to remove any antibody responses due to a current or recent
infection. Spearman correlation coefficients (r) between all
antibody responses and age (in years) were plotted using the
R package corrplot (36). Only pairwise complete observations
were used. The Bonferroni correction for multiple-comparisons
was used to adjust the p-value for statistical significance.
The chi-squared test for trend in proportions was used to
test age-specific trends in seroprevalence [stats package in
R (35)].
Antibody Responses Associated With Current or
Recent Exposure
In absence of a gold standard for recent exposure (i.e., confirmed
recent infection), hsRDT was used to determine antibody
responses associated with current or recent exposure. The hsRDT
detects histidine-rich protein 2 (HRP2), a P. falciparum antigen.
HRP2 has been shown to persist in the blood up to weeks after
parasite clearance following effective antimalarial treatment (37).
The hsRDT has a lower limit of detection for HRP2 antigenemia
(40–125 pg/mL HRP2) compared to the cRDT (600–1000 pg/mL
HRP2) (38) and is thus potentially more sensitive to (chronic)
low-density infections producing only low levels of HRP2. A
positive hsRDT result may therefore indicate a current or recent
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TABLE 2 | Characteristics of multiplex bead assay Plasmodium falciparum antigen panel.
Antigen Antigen
acronym
Alias Life cycle
stage/location
Expression tag Strain Reference
Circumsporozoite surface protein rCSP rcsp Sporozoite N/A 3D7 (17)
Liver surface antigen 1 LSA-1 lsa1 Infected hepatocyte N/A Synthesized peptide,
Pl1043 epitope
(18)
Plasmodium exported protein Hyp 2 hyp2 Hypothesised location:
iRBC
GST 3D7 (9); K.K.A. Tetteh,
unpublished
Heat shock protein 40 HSP40 ag 1 hsp40 iRBC GST 3D8 (9); K.K.A. Tetteh,
unpublished
Schizont egress antigen SEA-1 sea iRBC GST 3D7 (19); K.K.A. Tetteh,
unpublished
Skeleton-binding protein;
Maurer’s cleft
SBP1 sbp1 iRBC GST 3D7 (20); K.K.A. Tetteh,
unpublished
Histidine rich protein 2 HRP2 hrp2 iRBC and secreted GST Type A and B (21)
Early transcribed membrane
protein
Etramp 4 ag 2 etr4 iRBC, PVM GST 3D7 (9); K.K.A. Tetteh,
unpublished
Early transcribed membrane
protein
Etramp 5 ag 1 etr5 iRBC, PVM GST 3D7 (22); K.K.A. Tetteh,
unpublished
Gametocyte exported protein 18 GEXP18 gexp iRBC/ Gametocyte GST 3D7 (9); K.K.A. Tetteh,
unpublished
CH150/9 allele of MSP2;
full-length.
MSP2 CH150/9 msp2_ch150 Merozoite surface GST CH150/9 (23)
Dd2 allele of MSP2; full-length. MSP2 Dd2 msp2_dd2 Merozoite surface GST Dd2 (24)
Glutamate rich protein R0 GLURP R0 glurp0 Merozoite surface N/A Synthesized peptide,
R0 fragment
(25)
Glutamate rich protein R2 GLURP R2 glurp2 Merozoite surface Hisx6 F32 (26)
19kDa fragment of MSP1
molecule
PfMSP-119 msp119 Merozoite surface GST Wellcome (27)
H103/merozoite surface protein
11
H103/MSP11 h103 Merozoite
surface/rophtry neck
GST 3D7 (28)
Erythrocyte binding antigen-140
Region III-V
EBA-140 RIII-V e140 Merozoite
(Micronemes)
GST 3D7 (29)
Erythrocyte binding antigen-175
Region III-V
EBA-175 RIII-V e175 Merozoite
(Micronemes)
GST 3D7 (29)
Erythrocyte binding antigen-181
Region III-V
EBA-181 RIII-V e181 Merozoite
(Micronemes)
GST 3D7 (29)
Apical membrane antigen 1 PfAMA1 ama1 Merozoite
(Micronemes)
His FVO (30)
Reticulocyte binding protein
homologue 2
Rh2_2030 rh2030 Merozoite (Rhoptry) GST 3D7 (31)
Reticulocyte binding protein
homologue 4
Rh4.2 rh42 Merozoite (Rhoptry) GST W2mef (32)
Reticulocyte binding protein
homologue 5
Rh5.1 rh5 Merozoite (Rhoptry) C-tag 3D7 (33)
MSP, merozoite surface protein; kDa, kilodalton; GST, Glutathione S-transferase; iRBC, infected red blood cell; PVM, parasitophorous vacuole membrane.
infection. Antibody responses to antigenic targets that were not
selected as cumulative exposure markers, were used to predict
hsRDT positivity using receiver operating characteristic (ROC)
curves. To assess utility to predict hsRDT infection status, only
participant data from EAG-Grand’Anse was used, which was
the survey with the highest rate of hsRDT positives. The EAG-
Grand’Anse data was split into a training dataset (two-third, n
= 3,201) and a test dataset (one-third, n = 1,648) using random
selection. The numbers of hsRDT positive samples in the training
dataset was 227 (7.1%) and in the test dataset was 120 (7.3%).
The area-under-the-curve (AUC) of ROCs [pROC package; (39)]
was measured using the training dataset in all ages as well as
separately for those aged 1 to 15 years and those aged older than
15 years to assess any differences by age. The performance of
the most informative antibody responses in predicting hsRDT
status (i.e., AUC >0.8) was confirmed by repeating ROCs for
the test, HH-Artibonite, and EAG-Artibonite datasets. Finally,
ROCs using seropositivity endpoints were also assessed in the
test dataset. ROCs were compared using DeLong’s test for two
correlated ROC curves [roc.test within the pROC package; (39)].
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FIGURE 1 | Heat map of Spearman correlation coefficients for age and immunoglobulin G (IgG) responses to seventeen Plasmodium falciparum antigens across three
malaria transmission surveys in Haiti. IgG responses were defined as log10-transformed median fluorescence intensities corrected for background reactivity, while age
is in years. Data is shown for 28,888 participants; highly sensitive rapid diagnostic test (hsRDT) positives were excluded (n = 536) to remove any IgG responses due to
a current or recent infection. Coloring represents the strength of Spearman correlation coefficients from weak in grey to strong in red. Antigens (x-axis) are ordered
from the lowest to highest Spearman correlation coefficient using data from all three surveys. Spearman correlation coefficients that were not statistically significant
(i.e., p > 0.003 assuming Bonferroni correction for multiple testing) are indicated with an asterisk (*); all other age and IgG comparisons had p-values < 0.001.
RESULTS
Selection of Antibodies Associated With
Cumulative Malaria Exposure
In the HH-Artibonite survey, antibody levels, log10(MFI)’s, to
most antigens showed weak positive associations with increasing
age (Spearman correlation coefficient, r ≤ 0.40; Figure 1). AMA-
1 and MSP-119 showed moderate correlation with age (0.47 and
0.43, p < 0.001). The correlation coefficient between AMA-1
and MSP-119 was 0.67, p < 0.001 (Supplementary Figure 2).
Together with GLURP-R2, these antigens were consistently the
top three in each survey, although MSP-119 showed a weaker
correlation (0.35, p < 0.001) than the other two antigens (≥0.38,
p < 0.001) in the EAG-Grand’Anse survey. The validation
of AMA-1 and MSP-119 as the most appropriate markers of
cumulative exposure is consistent with the literature across
multiple settings (2, 40–42). A strong age-related increase in
seroprevalence to the combined metric of cumulative exposure
(i.e., seropositivity to either AMA-1 or MSP-119) was seen across
all surveys (chi-squared test for trend in proportions, p < 0.001).
Selection of Antibodies Associated With
Current or Recent Malaria Exposure
Antibody levels to the remaining 14 targets were included
to predict hsRDT status using ROCs and a training dataset
consisting of two-thirds of the EAG-Grand’Anse participants.
Etramp 5 ag 1 had the highest AUC for predicting hsRDT status
(0.892), followed by GLURP-R0 (0.825); Figure 2. Responses to
the remaining antigens had an AUC ≤ 0.8. For all antigens
except GLURP-R0, the AUC for children aged 1 to 15 was
greater than that for individuals aged 16 or older. There were
clear differences in AUCs between these age groups for some
antibodies (e.g., HRP-2 and HSP40) while for others AUCs
were similar (e.g., LSA-1 and rCSP). For children aged 15
or younger—in addition to Etramp 5 ag 1 and GLURP-R0—
SBP-1, Etramp 4 ag 2, HSP40 ag 1 and EBA-175 RIII-V had
an AUC > 0.8.
The performance of antibodies to Etramp 5 ag 1 and GLURP-
R0 as accurate markers for hsRDT status (i.e., AUC>0.8)
was confirmed in the test dataset (Figure 3) as well as the
HH- and EAG-Artibonite surveys (Supplementary Figure 3).
Using seropositivity, for all age categories, Etramp 5 ag 1
showed similar performance compared to GLURP-R0 (all ages:
p = 0.118; children aged 1 to 15: p = 0.060; individuals
aged 16 or older: p = 0.686) and the combined metric,
representing seropositivity to either Etramp 5 ag 1 or GLURP-
R0 (p = 0.266; p = 0.257; p = 0.733). As no improvement
was seen by adding GLURP-R0, Etramp 5 ag 1 alone was
selected to represent recent exposure to falciparum malaria.
Age-specific hsRDT and seroprevalence per survey is shown
in Figure 4.
DISCUSSION
This study used multiplex serological data to select antigen-
specific antibody responses associated with cumulative and
current or recent malaria exposure in Haiti. IgG responses from
almost 30,000 participants were analyzed from three surveys
across two locations with differing levels of malaria transmission
intensity. Results showed that IgG responses to antigens AMA-1
andMSP-119 best reflected cumulative exposure over time, whilst
those to Etramp 5 ag 1 showed the highest accuracy in predicting
current or recent infection when compared to hsRDT status. For
the latter, survey data was used from the area experiencing the
highest malaria transmission (Grand’Anse).
Continuous antibody responses to AMA-1 and MSP-119
were confirmed as the optimum representation of cumulative
malaria exposure as they showed the strongest correlation
with age. These antigens have been used extensively in sero-
surveillance for P. falciparum transmission (2). Seroconversion
rates to AMA-1 and/or MSP-119 have shown a strong correlation
with household altitude (42), EIR (2, 42), child mortality (43,
Frontiers in Immunology | www.frontiersin.org 6 May 2020 | Volume 11 | Article 928
van den Hoogen et al. Plasmodium falciparum Antibodies in Elimination
FIGURE 2 | Area under the curve (AUC) of receiver operating characteristic curves for immunoglobulin G (IgG) responses to fourteen Plasmodium falciparum antigens
using highly sensitive rapid diagnostic test (hsRDT) status as the gold standard. Antigens (x-axis) are ordered by parasite life cycle stage and AUC value for all ages.
IgG responses (IgG) in two-thirds of all EAG-Grand’Anse participants were used (i.e., the training dataset; n = 3,201) including 227 hsRDT positives (7.1%). IgG
responses were defined as log10-transformed median fluorescence intensities corrected for background reactivity. A threshold of 0.8 (dashed horizontal line) was
used to select antigens for confirmation of results in the remaining one-third of the EAG-Grand’Anse dataset (see Figure 3). Spor.: sporozoite; Hep.: infected
hepatocyte; iRBC: infected red blood cell.
44), the effect of malaria control interventions (43, 45), and
patterns in malaria transmission over time (44). In addition,
GLURP-R2 was moderately correlated with age. GLURP-R2 has
been associated with protection from (symptomatic) malaria
(46, 47) as well as cumulative exposure (40, 48). This study
shows strong indications that seropositivity to AMA-1, MSP-
119, and to a lesser extent, GLURP-R2, represent cumulative
exposure in this Haitian population. Some previous studies
have found that AMA-1 and MSP-119 can be good markers
of active and recent infection in children (7, 8, 41), though
at higher transmission, even in children, repeated exposure
and subsequent antibody boosting limits their use as recent
exposure markers (9). Given that we have confirmed the
appropriateness of AMA-1 and MSP-119 as a cumulative
marker of exposure in Haiti, there is an added benefit
of enabling comparisons of results across malaria-endemic
settings due to their extensive use in sero-surveillance to
date (2, 40–42).
Next, continuous antibody responses were used to validate
markers of current or recent P. falciparum exposure according
to hsRDT results. Etramp 5 ag 1 and GLURP-R0 were
found to be most accurate in predicting hsRDT status in
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FIGURE 3 | Receiver operating characteristic curves for immunoglobulin G (IgG) responses to selected Plasmodium falciparum antigens using highly sensitive rapid
diagnostic test (hsRDT) status as the gold standard. IgG responses in one-thirds of all EAG-Grand’Anse participants were used (i.e., the test dataset; n = 1,648)
including 120 hsRDT positives (7.3%). IgG responses were defined as log10-transformed median fluorescence intensities corrected for background reactivity. Results
are shown for continuous IgG responses (top) for antigens with an area-under-the-curve (AUC) > 0.8 in the training dataset (Figure 2). Seropositivity results (bottom)
are only shown for antigens with an AUC > 0.8 using continuous IgG responses in the test dataset (top). AUC values are depicted on each plot. From left to right
results are shown for: all ages, children aged 1 to 15 years and individuals older than 15 years.
the EAG-Grand’Anse survey. As no further improvement was
seen by combining seropositivity to GLURP-R0 and Etramp 5
ag 1, seropositivity to Etramp 5 ag 1 alone was selected as
representative of current or recent exposure to malaria. For
children – in addition to Etramp 5 ag 1 and GLURP-R0 – SBP-
1, Etramp 4 ag 2, HSP40 ag 1, and EBA-175 RIII-V showed
high accuracy in predicting hsRDT status. Intuitively, antibody
responses in young children are more likely to represent a recent
infection as they are unlikely to have developed a robust memory
response following multiple infections (49), especially in areas
of low transmission. Here we showed that all antibodies tested,
except those to GLURP-R0, had higher accuracy in predicting
hsRDT status in children compared to individuals aged 16 or
older. Ideally, an IgG antibody response representing recent
exposure does so across all ages as it minimizes the antigen panel
needed. IgM antibody responses have regularly been suggested
as a measure of recent exposure following their rapid acquisition
and decline in viral infections, however, recent data showed IgM
responses to malaria persisted over time and were not more
short-lived than IgG responses to merozoite antigens (50).
Age-specific patterns of recent and cumulative exposure
were consistent with expected exposure histories in the two
transmission settings in Haiti: (1) recent exposure was higher
in EAG-Grand’Anse compared to EAG-Artibonite which
corresponds with the 2017 malaria incidence estimated at 18.1
and 0.6 per 1,000 inhabitants in Grand’Anse and Artibonite,
respectively (source: National Malaria Control Program, PNCM,
Haiti); (2) recent exposure was higher in healthcare-seeking
populations compared to (likely asymptomatic) children
attending school in Grand’Anse; (3) recent exposure was similar
in children visiting a health facility or attending school in
Artibonite, indicating that in this low transmission setting,
healthcare-seeking is likely not driven by malaria disease; (4)
cumulative and recent exposure was lowest in the HH-Artibonite
survey representing an asymptomatic, community-based
population across all ages.
The gold standard for identification of antibodies with short
(or longer) half-lives, is assessment of antibody acquisition and
decay rates in longitudinal studies following naturally acquired
malaria infections. However, such studies are costly, time and
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FIGURE 4 | Highly sensitive rapid diagnostic test (hsRDT) prevalence as well as recent and cumulative exposure seroprevalence per age category (in years) and
survey in Haiti. Recent exposure represents seropositivity to early transcribed membrane protein 5 (Etramp 5 ag 1) while cumulative exposure represents seropositivity
to apical membrane antigen 1 (AMA-1) and/or the 19 kDa fragment of merozoite surface protein 1 (MSP-119).
labor intensive, and thus rare. Moreover, no existing studies
have used the same combination of the age range of the study
population, antigen panel assessed and assay conditions (9, 25,
40). Here we used hsRDT data from cross-sectional surveys to
inform the selection of current or recent exposure markers. It
was assumed that the lack in specificity in using antibody levels
to predict hsRDT status represented recent malaria infections
that had become hsRDT negative. Alternatively, these could be
malaria infections below the limit of detection of the hsRDT.
The lack in sensitivity might represent infections that are too
recently acquired for an antibody response to have developed.
Alternatively, certain individuals may not produce detectable
antibodies to a specific antigen following infection. The overlap
in identified recent exposure markers with previous longitudinal
studies [Etramp 5 in Helb et al. (9) and GLURP-R0 in Kerkhof
et al. (25)] is promising for selection and standardization of
antigen panels for sero-surveillance (51). However, Kerkhof
et al. also identified GLURP-R2 and MSP-119 as recent exposure
markers (25)—but these were better markers of cumulative
exposure in our and other (42–45, 48) studies—indicating
the need for caution and validation of these targets across
populations and differing (histories of) transmission intensities.
In settings with lower transmission, such as in Cambodia in
the Kerkhof study (25), antibody levels are more likely to be
reflective of recent exposure as they are not boosted following
the lack of repeated exposure. This was also seen in our study,
as nearly all antigen-specific antibodies analyzed accurately
predicted hsRDT status in the Artibonite surveys where hsRDT
prevalence was <1%.
There are different statistical techniques available to analyze
multiplex antibody data. Boosted regression tree analysis has
been used for P. vivax and P. knowlesi (52, 53). These studies
showed that combined immune responses are more likely
to be reflective of (recent) exposure though increments are
small. It should be noted that the selection of antibodies for
recent and cumulative exposure as described in this study
is not meant to be exclusive. Remaining antibody responses
may still be of interest for research-based studies interested in
responses to, and patterns in, antibodies to specific targets. The
antigens identified here were selected to enable rapid turnaround
of analyses to directly inform malaria control programs
in Haiti.
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Here we described the selection of antibodies associated
with cumulative and recent malaria exposure in Haiti. We
used antibody responses (IgG) to 23 P. falciparum recombinant
proteins and peptides from 29,481 participants across three
surveys. In the absence of a gold standard (i.e., longitudinal
data), we used age and hsRDT status to make this selection.
Seropositivity to AMA-1 and/or MSP-119 was selected to
represent cumulative malaria exposure, while seropositivity to
Etramp 5 ag 1 was selected to represent recent exposure to
malaria. The identification of these antimalarial antibodies will
simplify analyses and interpretation where results are needed to
inform program decisions in Haiti.
DATA AVAILABILITY STATEMENT
The datasets generated for this study are available on request to
the corresponding author.
ETHICS STATEMENT
The EAG-Artibonite and EAG-Grand’Anse surveys were
approved by the London School of Hygiene and Tropical
Medicine (LSHTM) Research Ethics Committee (10393), Tulane
Institutional Review Board (794709) and the National Bioethics
Committee in Haiti (1516-30). The Center for Global Health
Associate Director of Science reviewed and approved the
protocols; Centers for Disease Control and Prevention (CDC)
investigators were not considered to be engaged in human
subjects research (protocol 2016-135a). The HH-Artibonite
survey was approved by the CDC Institutional Review Board
(6821), LSHTM Research Ethics Committee (10466) and the
National Bioethics Committee in Haiti (1516-29 and 1617-31).
For the EAG-Artibonite and EAG-Grand’Anse surveys,
consent was collected from school directors following
community meetings to inform parents and allow opt-out.
At health facilities, adult participants provided consent directly,
and consent for children (<18 years) was provided by a parent
or guardian and children above 6 years gave assent to participate.
Individuals aged 16 or 17 who were married, head of household,
or a parent were considered ‘mature minors’ and consented
directly. Thumbprint consent or assent (countersigned by
a witness) was used for illiterate participants. For the HH-
Artibonite survey, verbal consent for overall permission to
conduct the survey was obtained from the head of household
and/or primary caretaker and documented in the electronic
data collection instrument. Individual-level verbal consent
was sought from each present individual for the blood sample
collection, and assent from persons aged 7–17 years.
AUTHOR CONTRIBUTIONS
JL, MC, TPE, TD, RA, GS, CD, KH, and ER designed the
surveys. TPE, TD, RA, VJ, GS, KH, and MC performed and
supported field data collection. KT, JGB, SS and ER provided
antigen constructs. JP, IR, TE, and GMperformed laboratory data
collection. LH, AE, JB, KT, CD, and ER supported laboratory data
collection. LH, GS, KT, ER, and CD analyzed and interpreted the
data. LHwrote the first draft of themanuscript with support from
GS and CD. All authors read and approved the final manuscript.
FUNDING
This study was conducted by the Malaria Zero Alliance
(http://malariazeroalliance.org/), funded by the Bill &
Melinda Gates Foundation through grant #OPP1114297 to
the CDC Foundation.
ACKNOWLEDGMENTS
The authors would like to thank all Malaria Zero field teams
for performing data collection as well as the survey participants.
We would like to acknowledge Professor Simon Draper and
Dr. Jing Jin (Jenner Institute, University of Oxford, Oxford,
United Kingdom) for provision of RH5.1 protein.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2020.00928/full#supplementary-material
REFERENCES
1. World Malaria Report. (2019). Available online at: https://www.who.int/
publications-detail/world-malaria-report-2019
2. Greenhouse B, Smith DL, Rodríguez-Barraquer I, Mueller I, Drakeley CJ.
Taking sharper pictures of malaria with CAMERAs: combined antibodies to
measure exposure recency assays. Am J Trop Med Hyg. (2018) 99:1120–7.
doi: 10.4269/ajtmh.18-0303
3. Bosomprah S. A mathematical model of seropositivity to malaria antigen,
allowing seropositivity to be prolonged by exposure. Malar J. (2014) 13:12.
doi: 10.1186/1475-2875-13-12
4. Corran P, Coleman P, Riley E, Drakeley C. Serology: a robust indicator
of malaria transmission intensity? Trends Parasitol. (2007) 23:575–82.
doi: 10.1016/j.pt.2007.08.023
5. Yman V, White MT, Asghar M, Sundling C, Sondén K, Draper SJ,
et al. Antibody responses to merozoite antigens after natural Plasmodium
falciparum infection: kinetics and longevity in absence of re-exposure. BMC
Medicine. (2019) 17:22. doi: 10.1186/s12916-019-1255-3
6. Wipasa J, Suphavilai C, Okell LC, Cook J, Corran PH, Thaikla K, et al.
Long-lived antibody and B Cell memory responses to the human malaria
parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog. (2010)
6:e1000770. doi: 10.1371/journal.ppat.1000770
7. Mugyenyi CK, Elliott SR, Yap XZ, Feng G, Boeuf P, Fegan G, et al. Declining
malaria transmission differentially impacts the maintenance of humoral
immunity to Plasmodium falciparum in children. J Infect Dis. (2017) 216:887–
98. doi: 10.1093/infdis/jix370
8. Kinyanjui SM, Conway DJ, Lanar DE, Marsh K. IgG antibody responses
to Plasmodium falciparum merozoite antigens in Kenyan children
have a short half-life. Malaria J. (2007) 6:82. doi: 10.1186/1475-28
75-6-82
9. Helb DA, Tetteh KKA, Felgner PL, Skinner J, Hubbard A, Arinaitwe E, et al.
Novel serologic biomarkers provide accurate estimates of recent Plasmodium
Frontiers in Immunology | www.frontiersin.org 10 May 2020 | Volume 11 | Article 928
van den Hoogen et al. Plasmodium falciparum Antibodies in Elimination
falciparum exposure for individuals and communities. Proc Natl Acad Sci
USA. (2015) 112:E4438–47. doi: 10.1073/pnas.1501705112
10. Wu L, Hall T, Ssewanyana I, Oulton T, Patterson C, Vasileva H,
et al. Optimisation and standardisation of a multiplex immunoassay of
diverse Plasmodium falciparum antigens to assess changes in malaria
transmission using sero-epidemiology. Wellcome Open Res. (2019) 4:26.
doi: 10.12688/wellcomeopenres.14950.1
11. Malaria Zero. Malaria Zero Alliance. Available online at: https://www.
malariazeroalliance.org/malaria-zero
12. WHO. Country Profiles. WHO. Available online at: http://www.who.int/
malaria/publications/country-profiles/2017/en/
13. Druetz T, Andrinopoulos K, Boulos L-M, Boulos M, Noland GS, Desir L, et al.
“Wherever doctors cannot reach, the sunshine can”: overcoming potential
barriers to malaria elimination interventions in Haiti.Malar J. (2018) 17:393.
doi: 10.1186/s12936-018-2553-5
14. Rogier E, Hamre KES, Joseph V, Plucinski MM, Presume J, Romilus I, et al.
Conventional and high-sensitivity malaria rapid diagnostic test performance
in two transmission settings: Haiti 2017. J Infect Dis. (2019) 221:786–95.
doi: 10.1093/infdis/jiz525
15. Hoogen LL van den, Présumé J, Romilus I, Mondélus G, Elismé T, Sepúlveda
N, et al. Quality control of multiplex antibody detection in samples from
large-scale surveys: the example of malaria in Haiti. Sci Rep. (2020) 10:1–10.
doi: 10.1038/s41598-020-57876-0
16. Druetz T, Stresman G, Ashton RA, van den Hoogen LL, Joseph V, Fayette C, et
al. Programmatic Options for Monitoring Malaria in Elimination Settings: Easy
Access Group Surveys to Investigate Plasmodium Falciparum Epidemiology
in Two Regions With Differing Endemicity in Haiti. BMC Medicine (2020).
in press. doi: 10.1186/s12916-020-01611-z
17. Kastenmüller K, Espinosa DA, Trager L, Stoyanov C, Salazar AM, Pokalwar
S, et al. Full-length Plasmodium falciparum circumsporozoite protein
administered with long-chain poly(I•C) or the Toll-like receptor 4 agonist
glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and
CD4+ T cell immunity and protection in mice. Infect Immun. (2013) 81:789–
800. doi: 10.1128/IAI.01108-12
18. Plucinski MM, Candrinho B, Chambe G, Muchanga J, Muguande O,
Matsinhe G, et al. Multiplex serology for impact evaluation of bed net
distribution on burden of lymphatic filariasis and four species of human
malaria in northern Mozambique. PLoS Negl Trop Dis. (2018) 12:e0006278.
doi: 10.1371/journal.pntd.0006278
19. Raj DK, Nixon CP, Nixon CE, Dvorin JD, DiPetrillo CG, Pond-Tor S, et al.
Antibodies to PfSEA-1 block parasite egress from RBCs and protect against
malaria infection. Science. (2014) 344:871–7. doi: 10.1126/science.1254417
20. Grüring C, Heiber A, Kruse F, Ungefehr J, Gilberger T-W, Spielmann
T. Development and host cell modifications of Plasmodium falciparum
blood stages in four dimensions. Nat Commun. (2011) 2:165.
doi: 10.1038/ncomms1169
21. Rogier E, Plucinski M, Lucchi N, Mace K, Chang M, Lemoine JF, et al.
Bead-based immunoassay allows sub-picogram detection of histidine-
rich protein 2 from Plasmodium falciparum and estimates reliability
of malaria rapid diagnostic tests. PLoS ONE. (2017) 12:e0172139.
doi: 10.1371/journal.pone.0172139
22. Spielmann T, Fergusen DJP, Beck H-P. etramps, a new Plasmodium falciparum
gene family coding for developmentally regulated and highly charged
membrane proteins located at the parasite-host cell interface. Mol Biol Cell.
(2003) 14:1529–44. doi: 10.1091/mbc.e02-04-0240
23. Polley SD, Conway DJ, Cavanagh DR, McBride JS, Lowe BS, Williams TN,
et al. High levels of serum antibodies to merozoite surface protein 2 of
Plasmodium falciparum are associated with reduced risk of clinical malaria
in coastal Kenya. Vaccine. (2006) 24:4233–46. doi: 10.1016/j.vaccine.2005.
06.030
24. Taylor RR, Smith DB, Robinson VJ, McBride JS, Riley EM. Human antibody
response to Plasmodium falciparum merozoite surface protein 2 is serogroup
specific and predominantly of the immunoglobulin G3 subclass. Infect
Immun. (1995) 63:4382–8. doi: 10.1128/IAI.63.11.4382-4388.1995
25. Kerkhof K, Sluydts V, Willen L, Kim S, Canier L, Heng S, et al.
Serological markers to measure recent changes in malaria at population
level in Cambodia. Malar J. (2016) 15:529. doi: 10.1186/s12936-016-
1576-z
26. Theisen M, Vuust J, Gottschau A, Jepsen S, Høgh B. Antigenicity and
immunogenicity of recombinant glutamate-rich protein of Plasmodium
falciparum expressed in Escherichia coli. Clin Diagn Lab Immunol. (1995)
2:30–4. doi: 10.1128/CDLI.2.1.30-34.1995
27. Burghaus PA, Holder AA. Expression of the 19-kilodalton carboxy-terminal
fragment of the Plasmodium falciparum merozoite surface protein-1 in
Escherichia coli as a correctly folded protein. Mol Biochem Parasitol. (1994)
64:165–9. doi: 10.1016/0166-6851(94)90144-9
28. Pearce JA, Mills K, Triglia T, Cowman AF, Anders RF. Characterisation
of two novel proteins from the asexual stage of Plasmodium
falciparum, H101 and H103. Mol Biochem Parasitol. (2005) 139:141–51.
doi: 10.1016/j.molbiopara.2004.09.012
29. Richards JS, Stanisic DI, Fowkes FJI, Tavul L, Dabod E, Thompson JK, et al.
Association between naturally acquired antibodies to erythrocyte-binding
antigens of Plasmodium falciparum and protection from malaria and high-
density parasitemia. Clin Infect Dis. (2010) 51:e50–60. doi: 10.1086/656413
30. Collins CR, Withers-Martinez C, Bentley GA, Batchelor AH,
Thomas AW, Blackman MJ. Fine mapping of an epitope
recognized by an invasion-inhibitory monoclonal antibody
on the malaria vaccine candidate apical membrane antigen
1. J Biol Chem. (2007) 282:7431–41. doi: 10.1074/jbc.M6105
62200
31. Reiling L, Richards JS, Fowkes FJI, Barry AE, Triglia T, Chokejindachai
W, et al. Evidence that the erythrocyte invasion ligand PfRh2 is
a target of protective immunity against Plasmodium falciparum
malaria. J Immunol. (2010) 185:6157–67. doi: 10.4049/jimmunol.10
01555
32. Stubbs J, Simpson KM, Triglia T, Plouffe D, Tonkin CJ, Duraisingh MT,
et al. Molecular mechanism for switching of P. falciparum invasion pathways
into human erythrocytes. Science. (2005) 309:1384–7. doi: 10.1126/science.111
5257
33. Jin J, Tarrant RD, Bolam EJ, Angell-Manning P, Soegaard M, Pattinson DJ,
et al. Production, quality control, stability, and potency of cGMP-produced
Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2
cells. NPJ Vaccines. (2018) 3:32. doi: 10.1038/s41541-018-0071-7
34. Rogier E, van den Hoogen L, Herman C, Gurrala K, Joseph V, Stresman G,
et al. High-throughput malaria serosurveillance using a one-step multiplex
bead assay.Malar J. (2019) 18:402. doi: 10.1186/s12936-019-3027-0
35. R Core Team. R: A Language and Environment for Statistical Computing.
Vienna: R Foundation for Statistical Computing (2017). Available online
at: https://www.R-project.org/
36. Wei T, Simko V. R package “corrplot”: Visualization of a Correlation Matrix
(Version 0.84). (2017). Available online at: https://github.com/taiyun/corrplot
37. Plucinski MM, McElroy PD, Dimbu PR, Fortes F, Nace D, Halsey ES,
et al. Clearance dynamics of lactate dehydrogenase and aldolase following
antimalarial treatment for Plasmodium falciparum infection. Parasit Vectors.
(2019) 12:293. doi: 10.1186/s13071-019-3549-x
38. Malaria Policy Advisory Committee Meeting. WHO Technical Consultation
on Research Requirements to Support Policy Recommendations on Highly
Sensitive Point-Of-Care Diagnostics for P. falciparum Malaria. Geneva: World
Health Organization (2018).
39. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC:
an open-source package for R and S+ to analyze and compare ROC curves.
BMC Bioinform. (2011) 12:77. doi: 10.1186/1471-2105-12-77
40. Ondigo BN, Hodges JS, Ireland KF, Magak NG, Lanar DE, Dutta S, et al.
Estimation of recent and long-term malaria transmission in a population by
antibody testing to multiple Plasmodium falciparum antigens. J Infect Dis.
(2014) 210:1123–32. doi: 10.1093/infdis/jiu225
41. McCallum FJ, Persson KEM, Fowkes FJI, Reiling L,Mugyenyi CK, Richards JS,
et al. Differing rates of antibody acquisition to merozoite antigens in malaria:
implications for immunity and surveillance. J Leukoc Biol. (2017) 101:913–25.
doi: 10.1189/jlb.5MA0716-294R
42. Drakeley CJ, Corran PH, Coleman PG, Tongren JE, McDonald SLR, Carneiro
I, et al. Estimating medium- and long-term trends in malaria transmission by
using serological markers of malaria exposure. Proc Natl Acad Sci USA. (2005)
102:5108–13. doi: 10.1073/pnas.0408725102
43. Cook J, Kleinschmidt I, Schwabe C, Nseng G, Bousema T, Corran PH, et al.
Serological markers suggest heterogeneity of effectiveness of malaria control
Frontiers in Immunology | www.frontiersin.org 11 May 2020 | Volume 11 | Article 928
van den Hoogen et al. Plasmodium falciparum Antibodies in Elimination
interventions on Bioko Island, equatorial Guinea. PLoS ONE. (2011) 6:e25137.
doi: 10.1371/journal.pone.0025137
44. van den Hoogen LL, Griffin JT, Cook J, Sepúlveda N, Corran P,
Conway DJ, et al. Serology describes a profile of declining malaria
transmission in Farafenni, The Gambia. Malar J. (2015) 14:416.
doi: 10.1186/s12936-015-0939-1
45. Cook J, Reid H, Iavro J, Kuwahata M, Taleo G, Clements A, et al. Using
serological measures to monitor changes in malaria transmission in Vanuatu.
Malar J. (2010) 9:169. doi: 10.1186/1475-2875-9-169
46. Kana IH, Singh SK, Garcia-Senosiain A, Dodoo D, Singh S,
Adu B, et al. Breadth of functional antibodies is associated with
Plasmodium falciparum merozoite phagocytosis and protection against
febrile malaria. J Infect Dis. (2019) 220:275–84. doi: 10.1093/infdis/
jiz088
47. Adu B, Cherif MK, Bosomprah S, Diarra A, Arthur FKN, Dickson EK,
et al. Antibody levels against GLURP R2, MSP1 block 2 hybrid and
AS202.11 and the risk of malaria in children living in hyperendemic
(Burkina Faso) and hypo-endemic (Ghana) areas. Malar J. (2016) 15:123.
doi: 10.1186/s12936-016-1146-4
48. Björkman A, Shakely D, Ali AS, Morris U, Mkali H, Abbas AK,
et al. From high to low malaria transmission in Zanzibar-challenges
and opportunities to achieve elimination. BMC Medicine. (2019) 17:14.
doi: 10.1186/s12916-018-1243-z
49. WhiteMT, Griffin JT, Akpogheneta O, Conway DJ, KoramKA, Riley EM, et al.
Dynamics of the antibody response to Plasmodium falciparum infection in
African children. J Infect Dis. (2014) 210:1115–22. doi: 10.1093/infdis/jiu219
50. Boyle MJ, Chan JA, Handayuni I, Reiling L, Feng G, Hilton A, et al. IgM
in human immunity to Plasmodium falciparum malaria. Sci Adv. (2019)
5:eaax4489. doi: 10.1126/sciadv.aax4489
51. Arnold BF, Scobie HM, Priest JW, Lammie PJ. Integrated serologic
surveillance of population immunity and disease transmission. Emerging
Infect Dis. (2018) 24:1188–94. doi: 10.3201/eid2407.171928
52. Fornace KM, Brock PM, Abidin TR, Grignard L, Herman LS, Chua TH,
et al. Environmental risk factors and exposure to the zoonotic malaria
parasite Plasmodium knowlesi across northern Sabah, Malaysia: a population-
based cross-sectional survey. Lancet Planet Health. (2019) 3:e179–86.
doi: 10.1016/S2542-5196(19)30045-2
53. Longley RJ, White MT, Takashima E, Brewster J, Morita M, Harbers M,
et al. Development and validation of serological markers for detecting
recent exposure to Plasmodium vivax infection. bioRxiv 481168. (2018).
doi: 10.1101/481168
Disclaimer: The findings and conclusions presented in this report are those of the
authors and do not necessarily reflect the official position of the Centers for Disease
Control and Prevention.
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 van den Hoogen, Stresman, Présumé, Romilus, Mondélus,
Elismé, Existe, Hamre, Ashton, Druetz, Joseph, Beeson, Singh, Boncy, Eisele, Chang,
Lemoine, Tetteh, Rogier and Drakeley. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 12 May 2020 | Volume 11 | Article 928
